Cargando…
A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab
BACKGROUND: Sarcomatoid renal cell carcinoma (SRCC) is associated with poor prognosis. Although there is no standard treatment for SRCC, recent studies have reported the effectiveness of immune checkpoint inhibitors. CASE: An 82‐year‐old Japanese man presented to our hospital with an incidental righ...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388173/ https://www.ncbi.nlm.nih.gov/pubmed/33656804 http://dx.doi.org/10.1002/cnr2.1356 |
_version_ | 1783742590205558784 |
---|---|
author | Tomioka, Masayuki Nakane, Keita Ozawa, Kaori Iinuma, Koji Suzui, Natsuko Miyazaki, Tatsuhiko Koie, Takuya |
author_facet | Tomioka, Masayuki Nakane, Keita Ozawa, Kaori Iinuma, Koji Suzui, Natsuko Miyazaki, Tatsuhiko Koie, Takuya |
author_sort | Tomioka, Masayuki |
collection | PubMed |
description | BACKGROUND: Sarcomatoid renal cell carcinoma (SRCC) is associated with poor prognosis. Although there is no standard treatment for SRCC, recent studies have reported the effectiveness of immune checkpoint inhibitors. CASE: An 82‐year‐old Japanese man presented to our hospital with an incidental right renal tumor. Abdominal computed tomography (CT) showed an exophytic tumor in the right kidney with suspected right iliopsoas muscle invasion. Laparoscopic right radical nephrectomy was performed. Histopathological diagnosis revealed a clear cell RCC with a spindle cell carcinoma component. CT performed 3 months after surgery revealed multiple bilateral lung metastases and local recurrence. Although the patient received tyrosine‐kinase inhibitors for treating multiple metastases, the lung metastases continued to gradually increase, and peritonitis carcinomatosis was observed. Thus, the patient was intravenously administered nivolumab once every 2 weeks. After nivolumab administration, lung metastases, local recurrence, and peritonitis carcinomatosis gradually reduced. After 20 months of nivolumab treatment, the patient achieved a complete response of multiple metastases on CT. CONCLUSION: Nivolumab may be used as a treatment option for sarcomatoid renal cell carcinoma with multiple metastases. |
format | Online Article Text |
id | pubmed-8388173 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83881732021-08-31 A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab Tomioka, Masayuki Nakane, Keita Ozawa, Kaori Iinuma, Koji Suzui, Natsuko Miyazaki, Tatsuhiko Koie, Takuya Cancer Rep (Hoboken) Case Reports BACKGROUND: Sarcomatoid renal cell carcinoma (SRCC) is associated with poor prognosis. Although there is no standard treatment for SRCC, recent studies have reported the effectiveness of immune checkpoint inhibitors. CASE: An 82‐year‐old Japanese man presented to our hospital with an incidental right renal tumor. Abdominal computed tomography (CT) showed an exophytic tumor in the right kidney with suspected right iliopsoas muscle invasion. Laparoscopic right radical nephrectomy was performed. Histopathological diagnosis revealed a clear cell RCC with a spindle cell carcinoma component. CT performed 3 months after surgery revealed multiple bilateral lung metastases and local recurrence. Although the patient received tyrosine‐kinase inhibitors for treating multiple metastases, the lung metastases continued to gradually increase, and peritonitis carcinomatosis was observed. Thus, the patient was intravenously administered nivolumab once every 2 weeks. After nivolumab administration, lung metastases, local recurrence, and peritonitis carcinomatosis gradually reduced. After 20 months of nivolumab treatment, the patient achieved a complete response of multiple metastases on CT. CONCLUSION: Nivolumab may be used as a treatment option for sarcomatoid renal cell carcinoma with multiple metastases. John Wiley and Sons Inc. 2021-03-03 /pmc/articles/PMC8388173/ /pubmed/33656804 http://dx.doi.org/10.1002/cnr2.1356 Text en © 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Reports Tomioka, Masayuki Nakane, Keita Ozawa, Kaori Iinuma, Koji Suzui, Natsuko Miyazaki, Tatsuhiko Koie, Takuya A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab |
title | A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab |
title_full | A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab |
title_fullStr | A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab |
title_full_unstemmed | A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab |
title_short | A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab |
title_sort | case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388173/ https://www.ncbi.nlm.nih.gov/pubmed/33656804 http://dx.doi.org/10.1002/cnr2.1356 |
work_keys_str_mv | AT tomiokamasayuki acaseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab AT nakanekeita acaseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab AT ozawakaori acaseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab AT iinumakoji acaseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab AT suzuinatsuko acaseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab AT miyazakitatsuhiko acaseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab AT koietakuya acaseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab AT tomiokamasayuki caseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab AT nakanekeita caseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab AT ozawakaori caseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab AT iinumakoji caseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab AT suzuinatsuko caseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab AT miyazakitatsuhiko caseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab AT koietakuya caseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab |